12 Month Price Forecast For MD
Distance to MD Price Forecasts
MD Price Momentum
๐ค Considering MEDNAX (MD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 4:04 AM UTC
MD Analyst Ratings & Price Targets
Based on our analysis of 18 Wall Street analysts, MD has a neutral consensus with a median price target of $16.00 (ranging from $15.00 to $19.00). The overall analyst rating is Buy (7.5/10). Currently trading at $14.05, the median forecast implies a 13.9% upside. This outlook is supported by 3 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Macdonald at Truist Securities, suggesting a 6.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MD Analyst Consensus
MD Price Target Range
Latest MD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MD.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 6, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $15.00 |
Dec 16, 2024 | Macquarie | Tao Qiu | Outperform | Initiates | $18.00 |
Nov 19, 2024 | Mizuho | Ann Hynes | Neutral | Maintains | $15.00 |
Nov 5, 2024 | Jefferies | Jack Slevin | Buy | Maintains | $18.00 |
Nov 5, 2024 | UBS | A.J. Rice | Neutral | Maintains | $16.50 |
Nov 4, 2024 | Deutsche Bank | Pito Chickering | Hold | Maintains | $15.00 |
Nov 4, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $16.00 |
Nov 4, 2024 | Mizuho | Ann Hynes | Neutral | Maintains | $15.00 |
Oct 7, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $13.00 |
Sep 26, 2024 | Jefferies | Jack Slevin | Buy | Upgrade | $14.00 |
Aug 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
Aug 9, 2024 | UBS | A.J. Rice | Neutral | Maintains | $10.50 |
Jul 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $8.00 |
Jun 7, 2024 | Deutsche Bank | Pito Chickering | Hold | Upgrade | $8.00 |
May 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
Mar 6, 2024 | Jefferies | Brian Tanquilut | Hold | Maintains | $9.00 |
Feb 21, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
Feb 21, 2024 | Mizuho | Ann Hynes | Neutral | Maintains | $9.00 |
Nov 30, 2023 | UBS | A.J. Rice | Neutral | Initiates | $9.50 |
Oct 11, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $15.00 |
Stocks Similar to MEDNAX Inc
The following stocks are similar to MEDNAX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MEDNAX Inc (MD) Financial Data
MEDNAX Inc has a market capitalization of $1.23B with a P/E ratio of 8.0x. The company generates $2.01B in trailing twelve-month revenue with a -12.6% profit margin.
Revenue growth is +0.9% quarter-over-quarter, while maintaining an operating margin of +10.3% and return on equity of -29.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

MEDNAX Inc (MD) Company Overview
About MEDNAX Inc
Provides specialized pediatric and maternal-fetal care.
The company operates a network of healthcare providers that deliver specialized care services for newborns, expectant mothers, and pediatric patients. It generates revenue primarily through hospital contracts and billing for clinical services provided by its affiliated medical professionals, including pediatric subspecialists and maternal-fetal medicine experts.
Founded in 1979 and based in Sunrise, Florida, the company previously operated under the name MEDNAX, Inc. It offers a wide range of pediatric subspecialty services and has a strong presence in hospital settings, focusing on areas such as neonatal care and pediatric cardiology, which positions it to benefit from ongoing healthcare demands in maternal and child services.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
5,450
CEO
Mr. Mark S. Ordan
Country
United States
IPO Year
1995
Website
www.pediatrix.comMEDNAX Inc (MD) Latest News & Analysis
NEO: The Conference for Neonatology, focused on advancing neonatology education, is taking place in Fort Lauderdale, Florida.
The NEO Conference highlights advancements in neonatology, potentially driving innovation and investment opportunities in healthcare, particularly for companies involved in neonatal care solutions.
Pediatrix Medical Group has scheduled its 2024 Fourth Quarter Conference Call/Webcast for February 20, 2025.
The scheduled conference call for Pediatrix Medical Group may indicate upcoming financial performance insights, impacting stock valuation and investor sentiment.
Pediatrix announced strategic initiatives aimed at enhancing shareholder value, according to a Business Wire report from Fort Lauderdale, Fla.
Pediatrix's strategic initiatives signal potential growth and improved profitability, likely boosting shareholder confidence and stock performance.
Pediatrix Medical Group (MD) and Avantor, Inc. (AVTR) are two Medical Services stocks that may appeal to value investors.
The comparison of Pediatrix Medical Group and Avantor highlights potential investment opportunities, guiding value investors in making informed decisions based on relative attractiveness.
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a streamlined approach for stock selection.
Zacks Style Scores can help investors identify high-potential stocks tailored to their strategies, enhancing decision-making and potentially improving returns.
MD is expected to experience future growth due to stable same-facility patient volume, inorganic initiatives, and a shift to a revenue cycle management structure.
Stable patient volume growth and strategic initiatives indicate potential for revenue increase and operational efficiency, signaling positive future performance for MD.
Frequently Asked Questions About MD Stock
What is MEDNAX Inc's (MD) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, MEDNAX Inc (MD) has a median price target of $16.00. The highest price target is $19.00 and the lowest is $15.00.
Is MD stock a good investment in 2025?
According to current analyst ratings, MD has 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MD stock?
Wall Street analysts predict MD stock could reach $16.00 in the next 12 months. This represents a 13.9% increase from the current price of $14.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MEDNAX Inc's business model?
The company operates a network of healthcare providers that deliver specialized care services for newborns, expectant mothers, and pediatric patients. It generates revenue primarily through hospital contracts and billing for clinical services provided by its affiliated medical professionals, including pediatric subspecialists and maternal-fetal medicine experts.
What is the highest forecasted price for MD MEDNAX Inc?
The highest price target for MD is $19.00 from at , which represents a 35.2% increase from the current price of $14.05.
What is the lowest forecasted price for MD MEDNAX Inc?
The lowest price target for MD is $15.00 from David Macdonald at Truist Securities, which represents a 6.8% increase from the current price of $14.05.
What is the overall MD consensus from analysts for MEDNAX Inc?
The overall analyst consensus for MD is neutral. Out of 18 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are MD stock price projections?
Stock price projections, including those for MEDNAX Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.